ArticleJournal of neuro-oncology2025
Patterns of response following gamma knife radiosurgery for tectal plate gliomas.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiotherapy for glioma in the AI era: current applications and future prospects.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTectal plate gliomas are slow-growing brainstem tumors often causing obstructive hydrocephalus. This study evaluates radiological response patterns and clinical outcomes of Gamma Knife radiosurgery (GKRS), a minimally invasive alternative for tumor control with lower risks than surgery.
methodsA retrospective analysis was conducted on 10 patients treated with GKRS for tectal plate gliomas between January 2014 and November 2023 at a tertiary Gamma Knife Centre. Inclusion criteria required a minimum follow-up of one year with radiological assessment. Tumor volume, dose parameters, radiological responses, and clinical outcomes were documented.
resultsThe cohort comprised six females and four males, with a median age of 13 years (range: 2-31 years). Hydrocephalus was managed with endoscopic third ventriculostomy (50%) or ventriculoperitoneal shunting (40%). Histopathological confirmation, available in 40% of cases, revealed WHO Grade 2 diffuse astrocytoma. The median tumor volume was 2.18 cc, and a marginal dose of 12 Gy was delivered at a 50% isodose line. Radiological follow-up (median: 24 months) demonstrated a gradual reduction in tumor size in 90% of cases, with a median volume reduction of 56.7%. One patient exhibited pseudoprogression, and no cases of cystic degeneration or sustained tumor growth were observed. Clinically, 80% of patients reported symptomatic improvement, while 20% remained stable. Minor adverse effects, primarily headaches, were noted in four patients.
conclusionGKRS is a safe, effective treatment for tectal plate gliomas, offering significant tumor control with minimal complications. It primarily results in gradual tumor shrinkage, making it a viable alternative when surgery is not feasible.
Indexed as
Identifiers
40202567What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.